Ashley Capoot,

Ashley Capoot is an associate reporter covering technology and general news at CNBC.com. She graduated from Northwestern University in June 2022 with a degree in journalism and international studies. Prior to joining CNBC, Ashley interned with the Chicago Tribune, NBC News, the Medill Investigative Lab, and the TODAY show. Her primary focus is on technology and general news stories that impact people's lives. She can be reached at ashley.capoot@nbcuni.com.

Biography:  https://www.cnbc.com/ashley-capoot/

70%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

50%

Examples:

  • The article provides a balanced view of the company's announcement without expressing any personal opinion or favoritism.

Conflicts of Interest

100%

Examples:

  • The article does not disclose any potential conflicts of interest.

Contradictions

15%

Examples:

  • The article states that Hims & Hers is introducing compounded GLP-1 injections, but it also mentions that oral medication kits have been available since the start and the new injections will be more expensive.

Deceptions

50%

Examples:

  • The article fails to mention that compounded GLP-1 medications are custom-made alternatives to brand drugs designed to meet a specific patient's needs and have not been reviewed by the FDA for safety and efficacy.

Recent Articles

Hims & Hers Health Offers Compounded GLP-1 Weight Loss Drugs at Fraction of Brand-Name Costs: What You Need to Know

Hims & Hers Health Offers Compounded GLP-1 Weight Loss Drugs at Fraction of Brand-Name Costs: What You Need to Know

Broke On: Monday, 20 May 2024 Hims & Hers Health offers GLP-1 weight loss drugs at a fraction of the cost through partnerships with compounded injectable medication manufacturers, despite FDA concerns and potential adverse events. The move comes as demand for these drugs soars due to their effectiveness in aiding weight loss efforts. Prices start at $199 a month, significantly lower than brand-name versions like Wegovy and Ozempic.